Purpose Of Review: To caution against premature proposals advocating change before epidemiological and clinical evidence warrants such a paradigm shift.
Recent Findings: Until 2007, all allergy societies advocated allergen avoidance for prevention and therapy in food allergy. Since then, new evidence has prompted careful re-evaluation of the literature. In primary prevention, delayed introduction of allergenic foods to prevent food allergy was removed from most recommendations. However, there is currently no evidence that allergenic foods ought to be introduced earlier than is recommended for complementary foods, at 4-6 months of age. Here we uphold the view against an emerging school of thought that early and deliberate exposure to allergenic foods may prevent or delay the onset food allergy. While notions of promoting early oral tolerance may have some merit in theory, in practice research remains inconclusive. Of recent development are treatment advances as regards established food allergy, using food allergens to induce tolerance in highly selected populations of allergic children. However, the investigators themselves strongly warn of significant risks and stress the need to optimize safety and understand longer-term implications before these trials can be applied to routine clinical practice. In this paper we endorse the current recommendation that children with confirmed food allergy should avoid foods implicated in immediate reactions.
Summary: It is currently inappropriate and potentially dangerous to advocate deliberate exposure to foods involved in serious reactions against current recommendations and particularly so among food allergic children until more basic and clinical research become available.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/ACI.0b013e328339ab25 | DOI Listing |
Front Allergy
January 2025
Department of Medicine, Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, CA, United States.
Food allergy poses substantial social, economic, and quality of life burdens which are even heavier for families that are struggling with food insecurity. In the United States (US), food insecurity disproportionately affects vulnerable and historically marginalized communities, such as Latino/a/x and Black households. Targeting these disparities via our recent Food Equality Initiative (FEI) research intervention was challenging due to the barriers faced by the target underserved populations, which included poor digital literacy, language barriers, and limited access to necessary resources.
View Article and Find Full Text PDFSci Rep
January 2025
Vaccine and Infectious Disease Organization (VIDO), University of Saskatchewan, Saskatoon, SK, Canada.
Bovine tuberculosis (BTB) is an infectious disease of livestock and wildlife species that is caused by pathogenic members of the Mycobacterium tuberculosis complex such as Mycobacterium bovis. Due to the introduction of M. bovis-infected bison in the 1920s, BTB is now endemic in wood bison (Bison bison athabascae) population within the Wood Buffalo National Park (WBNP) in northern Canada.
View Article and Find Full Text PDFCell Mol Gastroenterol Hepatol
January 2025
Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Pediatrics, Perelman School of Medicine at University of Pennsylvania. Electronic address:
Background & Aims: Eosinophilic esophagitis (EoE) is a chronic esophageal inflammatory disorder characterized by eosinophil-rich mucosal inflammation and tissue remodeling. Prior research has revealed the upregulation of interferon (IFN) response signature genes (ISGs) in biopsy tissue from EoE patients, but the specific cell types that contribute to this IFN response and the effect of interferons on the esophageal epithelium remain incompletely understood. Here, we use scRNA-seq to examine the expression of IFN and ISGs during EoE and explore how IFN-α and IFN-γ treatments affect epithelial function.
View Article and Find Full Text PDFAm J Rhinol Allergy
January 2025
Department of Otolaryngology-Head and Neck Surgery, University of California, Irvine, Orange, CA, USA.
Background: Dupilumab was first approved by the United States Food and Drug Administration in 2017 for atopic dermatitis and has since been approved for many other indications. The use of dupilumab has grown, but industry payments to physicians have yet to be explored.
Objective: The study objective is to characterize the change in payments by pharmaceutical companies to physicians for dupilumab-related promotional activities.
Curr Med Res Opin
January 2025
Northwestern Medicine, Feinberg School of Medicine, Chicago, IL, United States.
Objective: To quantify treatment preferences for food allergy management options (oral immunotherapy, biologic therapy, and allergen avoidance), overall and by sociodemographic strata.
Methods: A US general population (≥13 years) discrete choice experiment (DCE) conducted comprised of 12 treatment-feature focused DCE choice sets; the Intolerance of Uncertainty─12 Scale (IUS-12); and clinical/demographic questions. Conditional logistic regression analyses were conducted overall and by age, income, urbanization, educational attainment, food and other sociodemographic factors, and presented as odds ratios (ORs) with 95% confidence intervals (CIs).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!